Quarter
Charts

BIOREGENX, INC.

BRGX

CIK 0001593184 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$386K
↓-16.3% -$75Kvs FY2024 (Q4)
Gross Profit
$319K
↓-1.2% -$4Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
67/100
  • Profitability
    100ROIC 35.1% (10% = solid, 20%+ = moat)
  • Liquidity
    0Current Ratio 0.06 (above 1.5 = solid)
  • Leverage
    100D/E -0.26 (under 0.5 = conservative)
  • Efficiency
    100Asset Turnover 4.03x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -16.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -1.7% · trend +231.3pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project BRGX's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$0.00
Total enterprise IV
$515K
Diluted shares
0.96B
Terminal PV
$373K (72% of total)
Year-5 FCF
$44K
YearProjected FCFDiscounted PV
+1$32K$29K
+2$35K$29K
+3$38K$28K
+4$41K$28K
+5$44K$27K
Terminal$601K$373K

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$9K
investment in PP&E
Stock-based comp (TTM)
$0
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$411K
everything owned
Total liabilities
$5M
everything owed
Stockholders' equity
$-5M
shareholder claim
Net debt
$1M
LT debt minus cash

Recent performance · 16 quarters

Revenue↓-16.3% -$75K
$386K
Net Income↑+79.6% +$314K
$-81K
Free Cash Flow
$67K
Operating Margin↑+53.2pts
-1.7%

Drill down

BRGX Sankey

See BIOREGENX, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

BRGX Charts

16 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

BRGX Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics